- Home
- LYRA
as 04-24-2025 4:00pm EST
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Upcoming Earnings Alert:
Get ready for potential market movements as Lyra Therapeutics Inc. LYRA prepares to release earnings report on 29 Apr 2025.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 6.1M | IPO Year: | 2020 |
| Target Price: | $1.25 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.08 - $5.65 | Next Earning Date: | 04-29-2025 |
| Revenue: | $1,534,000 | Revenue Growth: | -1.54% |
| Revenue Growth (this year): | -23.66% | Revenue Growth (next year): | 237.15% |
Latest Lyra Therapeutics Inc. News
LYRA Breaking Stock News: Dive into LYRA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Zacks
3 months ago
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know
Simply Wall St.
5 months ago
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
5 months ago
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
5 months ago
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
6 months ago
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
GlobeNewswire
7 months ago
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Simply Wall St.
8 months ago
Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value
Compare LYRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYRA Lyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.